Healthcare / Drug Manufacturers - Specialty & GenericKSE
$18010.00
-580.00 (-3.08%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-90.4B · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$736.4B
P/E
4.2x
↓EV/EBITDA
4.2x
↓ROE
14.9%
↑Gross Margin
53.3%
↑Debt/Equity
0.75
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.8%
FCF CAGR
—
FCF margin
-4.4%
FCF / Net income
-0.52x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.07T · net income $175.06B · FCF $-90.38B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2068.37B | $2068.37B | $1936.92B | $1813.84B | $1697.34B |
| Net Income | $175.06B | $175.06B | $57.89B | $152.67B | $102.57B |
| EBITDA | $320.37B | $320.37B | $182.13B | $270.74B | $211.56B |
| EPS | 4280.00 | 4280.00 | 1416.00 | 3692.00 | 2467.00 |
| Gross Margin | 53.3% | 53.3% | 54.2% | 51.3% | 53.0% |
| Operating Margin | 12.7% | 12.7% | 14.6% | 10.8% | 12.2% |
| Net Margin | 8.5% | 8.5% | 3.0% | 8.4% | 6.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.75 | 0.75 | 0.69 | 0.48 | 0.54 |
| Current Ratio | 1.20 | 1.20 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-90.38B | $-90.38B | $-173.92B | $-23.30B | $31.46B |
| Returns | |||||
| ROE | 14.9% | 14.9% | 5.8% | 16.3% | 12.4% |
| Valuation | |||||
| P/E | 4.21 | 4.21 | 15.08 | 5.41 | 7.78 |
| EV/EBITDA | 4.24 | 4.24 | 7.49 | 4.11 | 4.98 |
| P/B | 0.63 | 0.63 | 0.88 | 0.88 | 0.96 |
| Growth & Yield | |||||
| Revenue Growth | 6.8% | 6.8% | 6.8% | 6.9% | — |
| EPS Growth | 202.3% | 202.3% | -61.6% | 49.7% | — |
| Dividend Yield | 1.1% | 1.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-28.0%
EPS terminal req.
$1598.09
Spread vs growth
230.3%
5Y implied EPS CAGR
-14.7%
EPS terminal req.
$1933.69
Spread vs growth
217.0%
10Y implied EPS CAGR
-3.1%
EPS terminal req.
$3114.22
Spread vs growth
205.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.6%
Start / end P/E
14.4x → 4.3x
EPS bridge
1416.00 → 4280.00
Residual
-142.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.